Abstract: The present invention provides a polypeptide, called EspA, which is secreted by pathogenic E. coli, such as the enteropathogenic (SPEC) and enterohemorrhagic (EHEC) E. coli. The invention also provides isolated nucleic acid sequences encoding EspA polypeptide, EspA peptides, a recombinant method for producing recombinant EspA, antibodies which bind to EspA, and a kit for the detection of EspA-producing E. coli.

Abstract: A polypeptide, called Tir (for translocated intimin receptor, which is secreted by attaching and effacing pathogens, such as the enteropathogenic (EPEC) and enterohemorrhagic (EHEC) E. coli. These bacterial pathogens inserts their own receptors into mammalian cell surfaces, to which the bacterial pathogen then adheres to trigger additional host signaling events and actin nucleation. Diagnosis of disease caused by pathogenic E. coli can be performed by the use of antibodies which bind to Tir to detect the protein or the use of nucleic acid probes for detection of nucleic acids encoding Tir polypeptide. Isolated nucleic acid sequences encoding Tir polypeptide, Tir peptides, a recombinant method for producing recombinant Tir, antibodies which bind to Tir, and a kit for the detection of Tir-producing E. coli are provided. A method of immunizing a host with Tir to induce a protective immune response to Tir or a second polypeptide of interest is also provided.

Abstract: The present invention relates to liposomes and virosomes and, more particularly, to liposomal and virosomal delivery systems for transporting materials such as drugs, nucleic acids and proteins.

Abstract: Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.

Abstract: The invention provides a method for treating an animal suffering from a disease associated with reduced activity of a lysosomal hexosaminidase by administering to the animal an effective amount of a compound which increases the activity of the hexosaminidase.

Abstract: The present invention provides novel and surprisingly effective methods for delivering nucleic acids to cells. These methods are based upon the discovery that the presence of endosomal membrane destabilizers (e.g., calcium) leads to a dramatic increase in the transfection efficiency of plasmids formulated as SPLP, or “stabilized plasmid-lipid particles.

Abstract: The present invention provides a family of bacterial acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. The invention amidases are characterized by a highly conserved 20 amino acid N-terminal region and four highly conserved histidine-containing regions and by having amidase activity, particularly amide hydrolase activity. The invention further provides methods for using the invention amidases in drug screening assays to determine compounds with antibiotic activity or compounds that inhibit activity or production of endogenous acyl glucosaminyl inositol amidase in bacteria. The invention further provides methods for detoxifying a toxic substance by contacting the toxic substance with an invention amidase, for example, by expression of the amidase under environmental conditions in a bacterium.

Abstract: A display has a screen which incorporates a light modulator. The screen may be a front projection screen or a rear-projection screen. Elements of the light modulator may be controlled to adjust the intensity of light emanating from corresponding areas on the screen. The display may provide a high dynamic range.

Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involved administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and method of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such an diabetes. The invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils, said process comprising contacting the cells with an inhibitor of fibril formation. In particular the process prepares cells for use in a method of treating diabetes.

Abstract: Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.

Abstract: Methods, apparatuses, media and signals for evaluating a vessel. One method includes receiving at least one measurement of a physical dimension of the vessel, and producing an indication of abnormality in the vessel, in response to the at least one received measurement and at least one population-based parameter for the vessel. Producing may include producing an indication of stenosis of the vessel, in response to the physical dimension measurement and a population-based reference dimension for the vessel. This may include producing a population-based percent stenosis value in response to a ratio of the physical dimension measurement to the population-based reference dimension. Producing may further include identifying a shape characteristic of the vessel, which may include producing a tapering comparison value in response to the tapering of the vessel and a population-based average tapering value. The vessel may include a coronary artery segment, for example.

Abstract: A brightness enhancing structure for a reflective display. A plurality of transparent hemi-beads form a film substantially covering and protruding inwardly from the structure's inward surface. A corresponding plurality of microstructured toroidal lenses are provided on the structure's outward side. Each lens is optically coupled to an adjacent one of the hemi-beads to redirect incident light rays toward the adjacent hemi-bead, such that the redirected light is totally internally reflected by the hemi-bead and reflected back in a direction approximately opposite that of the incident rays. This substantially reduces undesirable dark, non-reflective circular regions of each hemi-bead which would otherwise exist in the absence of this invention.

Abstract: The present invention provides a polypeptide, called EspA, which is secreted by pathogenic E. coli, such as the enteropathogenic (SPEC) and enterohemorrhagic (EHEC) E. coli. The invention also provides isolated nucleic acid sequences encoding EspA polypeptide, EspA peptides, a recombinant method for producing recombinant EspA, antibodies which bind to EspA, and a kit for the detection of EspA-producing E. coli.

Abstract: The light emitting surface of an image display light box is formed of multi-layer optical film having a reflectance greater than 95% and preferably about 99% or greater. This more efficiently utilizes light rays emitted by the light box's internal light source, since the multi-layer optical film reflects the light rays many times before the rays are absorbed and lost. Consequently, the light emitting surface can have a light transmissivity characteristic which is macroscopically invariant as a function of position on the light emitting surface. Light boxes utilizing prior art reflective materials require cumbersome, time-consuming, iterative trial and error techniques which must be customized for each light box in order to compensate for light absorption losses by imparting a variable transmissivity characteristic to the reflective material.

Abstract: Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation.

Abstract: New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R1 is independently alkyl (1–6C); each n is independently an integer of 0–6; and R2 is vinyl or a derivative form thereof.

Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.

Abstract: A brightness enhancing structure for a reflective display. A plurality of transparent hemi-beads form a film substantially covering and protruding inwardly from the structure's inward surface. A corresponding plurality of microstructured toroidal lenses are provided on the structure's outward side. Each lens is optically coupled to an adjacent one of the hemi-beads to redirect incident light rays toward the adjacent hemi-bead, such that the redirected light is totally internally reflected by the hemi-bead and reflected back in a direction approximately opposite that of the incident rays. This substantially reduces undesirable dark, non-reflective circular regions of each hemi-bead which would otherwise exist in the absence of this invention.

Abstract: A display has a screen which incorporates a light modulator. The screen may be a front projection screen or a rear-projection screen. Elements of the light modulator may be controlled to adjust the intensity of light emanating from corresponding areas on the screen. The display may provide a high dynamic range.

Abstract: The present invention discloses novel polymer-ceramic matrix composites and processes for making same. The composites can be used in biomedical applications, in particular, coatings of implants and other medical devices, where both the ceramic phase and the polymer phase are bio-compatible. The composites combine a reinforcing polymer phase with a continuous ceramic matrix to create materials with properties that are new and superior to polymer or ceramic phases alone. The composites can incorporate a bioactive agent.